Cantor Fitzgerald Reiterates Neutral on Karuna Therapeutics, Maintains $330 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan has reiterated a Neutral rating on Karuna Therapeutics (NASDAQ:KRTX) and maintained a price target of $330.

January 17, 2024 | 4:26 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cantor Fitzgerald analyst reaffirms Neutral rating on Karuna Therapeutics with a $330 price target.
The reiteration of a Neutral rating and maintenance of the price target suggests no significant change in the analyst's view on the company's stock, which is likely to have a neutral short term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100